This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
by Zacks Equity Research
The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.
Beat the Market the Zacks Way: DaVita, Block, Home Depot in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
by Zacks Equity Research
Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
by Zacks Equity Research
Sales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of the Pompe disease drug combination, Pombiliti + Opfolda, is a positive.
Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study
by Zacks Equity Research
Though data from a mid-stage study shows that treatment with Aclaris' (ACRS) JAK inhibitor met its primary endpoint, it also displays a greater-than-expected placebo effect.
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
by Zacks Equity Research
Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.
Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%
by Zacks Equity Research
Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.
Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel
by Zacks Equity Research
Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline
by Zacks Equity Research
Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
by Zacks Equity Research
Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
by Zacks Equity Research
Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why
by Zacks Equity Research
MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.
Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal
by Zacks Equity Research
Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.
Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy
by Zacks Equity Research
The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
by Zacks Equity Research
Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
by Zacks Equity Research
After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
by Zacks Equity Research
Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
by Zacks Equity Research
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
by Zacks Equity Research
Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug
by Zacks Equity Research
The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.
J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag
by Zacks Equity Research
FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry
by Zacks Equity Research
Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
by Zacks Equity Research
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
by Zacks Equity Research
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.